# A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

> **NCT07034508** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 134 (estimated)

## Conditions studied

- DLBCL - Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT07034508
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2027-12-20
- **Final completion:** 2029-12-20
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07034508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07034508, "A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07034508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*